Skip to main content
Clinical Trials/NCT07320703
NCT07320703
Recruiting
Not Applicable

"Breathlessness Diagnostics in a Box" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design

General Practitioners Research Institute3 sites in 3 countries900 target enrollmentStarted: August 5, 2024Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
General Practitioners Research Institute
Enrollment
900
Locations
3
Primary Endpoint
Time to diagnosis of the cause of breathlessness

Overview

Brief Summary

This prospective stepped-wedge study evaluates whether use of the Breathlessness diagnostics in a Box (BiaB) tool shortens the time to diagnosis in patients presenting with breathlessness, compared with usual care. The study is conducted in general practice settings in the Netherlands, Spain, and Portugal. Participating sites start with a usual care period and transition sequentially to the BiaB intervention period. Data are collected during routine clinical visits, from electronic medical records, and through questionnaires completed by patients and healthcare professionals.

Detailed Description

This is a prospective interventional study using a stepped-wedge cluster design with a usual care period followed by an intervention period. Participating general practice sites are assigned to one of five predefined sequences determining the timing of transition from usual care to the BiaB intervention. All sites start in the usual care phase and sequentially transition to the intervention phase according to the study schedule.

The primary objective of the study is to assess whether use of BiaB shortens the time to diagnosis in patients presenting with breathlessness, compared with usual care without BiaB. Secondary objectives include evaluating whether BiaB increases the number of new diagnoses of chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD), and assessing the usability and efficiency of the BiaB tool.

The study is conducted in general practice settings in the Netherlands, Spain, and Portugal, with a total of 45 sites. Each site participates for a total duration of 40 weeks. Patients attend a single study visit and may complete up to four quarterly questionnaires over a maximum follow-up of one year. Data are collected during routine clinical care, from electronic medical records, and via questionnaires completed by patients and healthcare professionals. Data from the usual care period, and where available retrospective data, are used as control data for comparison with the intervention period.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • The study aims to capture the real-world heterogeneity in primary care practices and patients. Therefore, inclusion and

Exclusion Criteria

  • are limited.
  • Inclusion criteria
  • Patient must be at least 18 years old at the time of signing the informed consent.
  • Patients that present with undiagnosed dyspnea (breathlessness); or Patients who have existing diseases that could cause breathlessness, but have residual or increasing breathlessness that could be caused by other not yet detected diseases. Or HCP has doubts or requires additional tests to confirm diagnosis or to suspect new, parallel, diagnoses. For example, breathlessness in patients assessed within the framework of Cardiovascular Risk Management or for COPD monitoring
  • Exclusion criteria
  • Acute worsening of previous diagnosed chronic disease where there is no suspicion of comorbidities (for example when a patient with clear COPD diagnosis has an exacerbation where typically the HCP will not perform additional tests).
  • Inability to understand and sign the written consent form.

Arms & Interventions

Usual care

No Intervention

Patients are managed according to usual care for the assessment of breathlessness in general practice, without use of the Breathlessness diagnostics in a Box (BiaB) tool. Clinical assessments, diagnostic procedures, and follow-up are performed as part of routine practice. Data collected during this period are used as control data for comparison with the intervention period.

BiaB Intervention

Experimental

Patients are managed using the Breathlessness diagnostics in a Box (BiaB) tool as part of routine clinical care. The BiaB intervention supports general practitioners in the diagnostic assessment of patients presenting with breathlessness. No study-mandated therapeutic interventions are applied. Outcomes during the intervention period are compared with those from the usual care period.

Intervention: Breathlessness diagnostics in a Box (BiaB) (Diagnostic Test)

Outcomes

Primary Outcomes

Time to diagnosis of the cause of breathlessness

Time Frame: From first presentation or consultation for breathlessness up to the date of diagnosis, assessed during the study period (up to 40 weeks per site).

Number of days between the first presentation or consultation for breathlessness and the date of diagnosis of the underlying cause of breathlessness, comparing periods of usual care and periods with use of the Breathlessness diagnostics in a Box (BiaB) intervention.

Secondary Outcomes

  • Number of new diagnoses of COPD and cardiovascular disease(Assessed during the study period (up to 40 weeks per site).)
  • Usability and efficiency of the BiaB tool(During the intervention period, with follow-up questionnaires completed up to 12 months after the index visit.)

Investigators

Sponsor
General Practitioners Research Institute
Sponsor Class
Network
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials